Amarantus BioScience

Amarantus is developing new treatments for PD-LID, #TBI, #AD, #MS, #RP & severe burns. #GBHC #LymPro #MANF #ESS #MSPrecise #Eltoprazine $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International https://t.co/waLoXoDtWZ $AMBS

[Financial Buzz TV @FinancialBuzzTV]

"Behind the Buzz" Show: Amarantus Bioscience Holdings, Inc. (OTC: $AMBS) CEO Gerald Commissiong

#Biotechnology #Diagnostics #Therapeutics #EmeraldOrganicProducts #Hempori #CBD #TodosMedical #ProvistaDx #Alzheimers #MANFTherapeutics #Glaucoma (Sponsored Financial News Content)

[Amarantus BioScience @AmarantusBio]

Amarantus Releases Letter to Shareholders https://t.co/YQFiJUWWr5 $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Acquires Majority Interest in CBD Wellness Company Hempori https://t.co/MHK2jt4BRP $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products https://t.co/pexRqKMEUR $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Provides Recapitalization Update to Shareholders https://t.co/1mnOv49l9u $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation https://t.co/FoQo3fFwY3 $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association https://t.co/VHJ56IDWjT $AMBS

[Amarantus BioScience @AmarantusBio]

Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference https://t.co/rOWmTz67TK

[Amarantus BioScience @AmarantusBio]

$AMBS President & CEO Gerald Commissiong recently presented at the 9th Annual LD Micro Invitational Conference. Listen to a webcast replay here: https://t.co/GxDMoox6kc

[Amarantus BioScience @AmarantusBio]

Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics https://t.co/B6DbL1qiEE $AMBS

[Amarantus BioScience @AmarantusBio]

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan https://t.co/oybMO8LHY3 $AMBS

[Amarantus BioScience @AmarantusBio]

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa https://t.co/45ON7pvANP $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries https://t.co/a9AqBft93v $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Provides 2019 Roadmap https://t.co/9p52jr0kBU $AMBS

[Amarantus BioScience @AmarantusBio]

Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0 https://t.co/i8mq2ct1bc

[Amarantus BioScience @AmarantusBio]

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma https://t.co/ZUHrDGlgPj $AMBS

[Amarantus BioScience @AmarantusBio]

Amarantus Provides Corporate Update https://t.co/CtmP2azPNn

[Amarantus BioScience @AmarantusBio]

MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology https://t.co/ax4SKupgqE

[Amarantus BioScience @AmarantusBio]

Amarantus Provides Update on Elto Pharma Capital Formation Plan https://t.co/Kxv7pQfNv2